Next Article in Journal
Effect of Antiepileptic Drugs on Plasma Fibrinogen Level
Previous Article in Journal
Different Types of Amyloid Concomitantly Present in the Same Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 12
Issue 1
10.4081/hr.2020.8267
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Comparison of Bortezomib-Cyclophosphamide-Dexamethasone versus Bortezomib-Dexamethasone Based Regimens in Newly Diagnosed Multiple Myeloma Patients

by
Rafiye Ciftciler
,
Hakan Goker
,
Yahya Buyukasik
,
Nilgun Sayınalp
,
Ibrahim C. Haznedaroglu
,
Salih Aksu
,
Osman Ozcebe
and
Haluk Demiroglu
*
Department of Hematology, Faculty of Medicine, Hacettepe University, 06230 Ankara, Turkey
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2020, 12(1), 8267; https://doi.org/10.4081/hr.2020.8267
Submission received: 3 August 2019 / Revised: 15 October 2019 / Accepted: 18 November 2019 / Published: 6 May 2020

Abstract

The treatment landscape and clinical outcome of multiple myeloma (MM) patients have changed in the last decades, with an improved median survival of 8–10 years. This study aimed to evaluate the bortezomib, cyclophosphamide and dexamethasone (VCD) regimen versus bortezomib and dexamethasone (VD) regimen in patients with newly diagnosed MM. This study has been performed in a retrospective manner. One hundred and three patients with newly diagnosed MM who received chemotherapy at our tertiary care center between the years of 2009 and 2018 were evaluated. A total of 103 patients were included. The 5-year overall survival (OS) for patients who received VD regimen and patients who received VCD regimen were 75% and 83%, respectively. The OS for VD patients was 113.1 ± 12.5 versus 122.2 ± 9.5 months for VCD patients with no statistically significant difference (p = 0.47). The 5-year PFS (progression free survival) for patients who received VD regimen and patients who received VCD regimen were 66% and 75%, respectively. The PFS for VCD patients was higher than the PFS for VD patients (67.1 ± 7.4 versus 97.7 ± 13.4 months), but no statistically significant difference was observed (p = 0.59). Relapse rate (p = 0.002) and mortality rate (p = 0.01) were higher in VD group than VCD group and they were statistically significant. The OS and PFS were clinically longer in patients receiving VCD regimen than in patients receiving VD regimen, although not statistically significant. Cyclophosphamide should be given to patients at physician discretion and depending on patient’s frailty function.
Keywords: multiple myeloma; VD regimen; VCD regimen multiple myeloma; VD regimen; VCD regimen

Share and Cite

MDPI and ACS Style

Ciftciler, R.; Goker, H.; Buyukasik, Y.; Sayınalp, N.; Haznedaroglu, I.C.; Aksu, S.; Ozcebe, O.; Demiroglu, H. Comparison of Bortezomib-Cyclophosphamide-Dexamethasone versus Bortezomib-Dexamethasone Based Regimens in Newly Diagnosed Multiple Myeloma Patients. Hematol. Rep. 2020, 12, 8267. https://doi.org/10.4081/hr.2020.8267

AMA Style

Ciftciler R, Goker H, Buyukasik Y, Sayınalp N, Haznedaroglu IC, Aksu S, Ozcebe O, Demiroglu H. Comparison of Bortezomib-Cyclophosphamide-Dexamethasone versus Bortezomib-Dexamethasone Based Regimens in Newly Diagnosed Multiple Myeloma Patients. Hematology Reports. 2020; 12(1):8267. https://doi.org/10.4081/hr.2020.8267

Chicago/Turabian Style

Ciftciler, Rafiye, Hakan Goker, Yahya Buyukasik, Nilgun Sayınalp, Ibrahim C. Haznedaroglu, Salih Aksu, Osman Ozcebe, and Haluk Demiroglu. 2020. "Comparison of Bortezomib-Cyclophosphamide-Dexamethasone versus Bortezomib-Dexamethasone Based Regimens in Newly Diagnosed Multiple Myeloma Patients" Hematology Reports 12, no. 1: 8267. https://doi.org/10.4081/hr.2020.8267

APA Style

Ciftciler, R., Goker, H., Buyukasik, Y., Sayınalp, N., Haznedaroglu, I. C., Aksu, S., Ozcebe, O., & Demiroglu, H. (2020). Comparison of Bortezomib-Cyclophosphamide-Dexamethasone versus Bortezomib-Dexamethasone Based Regimens in Newly Diagnosed Multiple Myeloma Patients. Hematology Reports, 12(1), 8267. https://doi.org/10.4081/hr.2020.8267

Article Metrics

Back to TopTop